Оптимізація базально-болюсної інсулінотерапії цукрового діабету 2-го типу на підставі фармакоекономічного аналізу


  • А. С. Колбін Державний університет, Санкт-Петербург



Ключові слова:

diabetes mellitus type 2, pharmacoeconomic, analogs of insulin


Pharmacoeconomic analysis of the use of insulin analogues for the treatment of patients with diabetes mellitus type 2 was conducted for substantiation of rationalization the allocation of public funds to improve the quality of medical care. It is shown that the most economical is the use of insulin glargine as monotherapy or combination with insulin glulisine for the treatment of patients with diabetes type 2 for whom the insulin therapy is recommended.

Біографія автора

А. С. Колбін, Державний університет, Санкт-Петербург

А.С. Колбин


IDF (International Diabetes Federation). Diabetes Atlas 3rd Edition. — 2006. — Р. 5.

Stumvoll M., Goldstein B., van Haeften T. Type 2 diabetes: principles of pathogenesis and therapy // Lancet. — 2005. — V. 365. — P. 1333–1346. https://doi.org/10.1016/s0140-6736(05)61032-x

Roglic G., Unwin N., Bennett P. et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000 // Diabetes Care. — 2005. — V. 28. — P. 2130–2135. https://doi.org/10.2337/diacare.28.9.2130

Gray R., Yudkin J. Cardiovascular disease in diabetes mellitus / In: Textbook of Diabetes 2nd Edition, 1997. Blackwell Sciences.

Stration M., Adlet A., Neil H. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) // BMJ. — 2000. — V. 321. — P. 405–412. https://doi.org/10.1136/bmj.321.7258.405

Nathan D., Buse J., Davidson M. et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes // Diabetes Care. — 2006. — V. 29. — P. 1963–1972. https://doi.org/10.2337/dc06-9912

Larme A., Pugh J. Attitudes of primary care providers toward diabetes: barriers to guideline implementation // Diabetes Care. — 1998. — V. 21. — P. 1391–1396. https://doi.org/10.2337/diacare.21.9.1391

Rossetti P., Porcellati F., Fanelli C. et al. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus // Arch Physiol. Biochem. — 2008. — V. 114 (1). — P. 3–10. https://doi.org/10.1080/13813450801900777

Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro // Diabetes. — 2000. — V. 49. — P. 2142–2148. https://doi.org/10.2337/diabetes.49.12.2142

Luzio S., Beck P., Owens D. Comparison of the subcutaneous absorption of insulin glargine (Lantus®) and NPH insulin in patients with type 2 diabetes // Horm. Metab. Res. — 2003. — V. 35. — P. 434–438. https://doi.org/10.1055/s-2003-41625

McMahon G., Dluhy R. Intention to treat — initiating insulin and the 4-T Study // N. Engl. J. Med. — 2007. — V. 357 (17). — P. 1759–1761. https://doi.org/10.1056/nejme078196

Gredal C., Rosenfalck A., Dejgaard A., Hilsted J. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes // Diabetes Res. Clin. Pract. — 2008. — V. 80 (2). — P. 293–298. https://doi.org/10.1016/j.diabres.2007.12.023

Apidra, prescribing information. Aventis Pharmaceuticals Kansas City, MO, USA (2004).

Becker R., Frick A., Burger F. et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique // Exp. Clin. Endocrinol. Diabetes. — 2005. — V. 113 (5). — P. 292-297. https://doi.org/10.1055/s-2005-865637

Becker R., Frick A., Burger F. et al. Insulin Glulisine, a New Rapid-Acting Insulin Analogue, Displays a Rapid Time-Action Profile in Obese Non-Diabetic Subjects // Exp. Clin. Endocrinol. Diabetes. — 2005. — V. 113 (8). — P. 435–443. https://doi.org/10.1055/s-2005-865806

Nosek L., Becker R., Frick A. et al. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin (Abstract) // Diabetes. — 2004. — V. 53. — P. A139.

Milicevic Z., Raz I., Beattie S. et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia // Diabetes Care. — 2008. — V. 31 (Suppl. 2). — S155–S160. https://doi.org/10.2337/dc08-s240

Brown J., Pedula K., Bakst A. The progressive cost of complications in type 2 diabetes mellitus // Arch. Intern. Med. — 1999. — V. 159. — P. 1873–1880. https://doi.org/10.1001/archinte.159.16.1873

Palmer J., Goodall G., Nielsen S. et al. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study // Curr. Med. Res. Opin. — 2008. — V. 24 (5). — P. 1417–1428. https://doi.org/10.1185/030079908x297295

Valentine W., Goodall G., Aagren M. et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes // Adv. Ther. — 2008. — V. 25 (6). — P. 567–584. https://doi.org/10.1007/s12325-008-0069-z

Белоусов Д.Ю. Фармакоэкономика инсулина гларгина (Лантус) по результатам зарубежных контролируемых исследований // Клин. фармакол. тер. — 2008. — Т. 17 (2). — С. 84–88.

Колбин А.С. Фармакоэкономика инсулина глулизин: увеличиваются ли затраты на государственное возмещение при сахарном диабете? // Кач. клин. практика. — 2008. — No 2. С. 47–52.

Колбин А.С. Фармакоэкономические аспекты применения аналогов инсулина. // Сахарный диабет. — 2008. — No 3. — С. 59-62. https://doi.org/10.14341/2072-0351-5363


Rosenstock J., Davies M., Home P. et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetologia. — 2008. — V. 51 (3). — P. 408–416. https://doi.org/10.1007/s00125-007-0911-x

Del Prato S., Nicolucci A., Vespasiani G. Optimising basal plus insulin therapy in type 2 diabetes by telecare assistance for self-monitoring of blood glucose — the ELEONOR study / 44-th Annual Meeting of EASD. — Roma, 2008. — A-08–2874.

Lee F., Zhang Q., Mersey J. et al. Glycaemic control and costs with insulin glargine plus glulisine versus premix — a randomized, prospective, observational study / 44-th Annual Meeting of EASD. — Roma, 2008. — A-08–1003.

Lankisch M., Ferlinz K., Scherbaum W. Adding a single dose of insulin glulisin at breakfast or main meal to basal insulin and oral antidiabetic therapy; which patients of the OPAL study benefit most? / 44-th Annual Meeting of EASD. — Roma, 2008. — A-08–2050.

Raslova K., Bogoev M., Raz I. et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes // Diabetes Res. Clin. Pract. — 2004. — V. 66. — P. 193–201. https://doi.org/10.1016/j.diabres.2004.03.003

Haak T., Tiengo A., Draeger E. et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes // Diabetes Obesity Metabol. — 2005. — V. 7. — P. 56–64. https://doi.org/10.1111/j.1463-1326.2004.00373.x

Liebl A., Prager R., Binz K. et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial // Diabetes Obes. Metabol. — 2008. https://doi.org/10.1111/j.1463-1326.2008.00915.x